



Activation of the Constitutive Androstane Receptor induces hepatic lipogenesis and regulates Pnpla3 gene expression in a LXR-independent way

Alice Marmugi, Céline Lukowicz, Frédéric Lasserre, Alexandra Montagner, Arnaud Polizzi, Simon Ducheix, Adeline Goron, Laurence Gamet-Payrastre, Sabine Gerbal-Chaloin, Jean-Marc Pascussi, et al.

► To cite this version:

Alice Marmugi, Céline Lukowicz, Frédéric Lasserre, Alexandra Montagner, Arnaud Polizzi, et al.. Activation of the Constitutive Androstane Receptor induces hepatic lipogenesis and regulates Pnpla3 gene expression in a LXR-independent way. *Toxicology and Applied Pharmacology*, 2016, 303, pp.90 - 100. 10.1016/j.taap.2016.05.006 . hal-01837194

HAL Id: hal-01837194

<https://hal.umontpellier.fr/hal-01837194>

Submitted on 27 May 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

Accepted Manuscript


Activation of the Constitutive Androstane Receptor induces hepatic lipogenesis and regulates *Pnpla3* gene expression in a LXR-independent way

Alice Marmugi, Céline Lukowicz, Frederic Lasserre, Alexandra Montagner, Arnaud Polizzi, Simon Ducheix, Adeline Goron, Laurence Payrastra, Sabine Gerbal-Chaloin, Jean Marc Pascussi, Marthe Moldes, Thierry Pineau, Hervé Guillou, Laila Mselli-Lakhal

PII: S0041-008X(16)30112-0
DOI: doi: [10.1016/j.taap.2016.05.006](https://doi.org/10.1016/j.taap.2016.05.006)
Reference: YTAAP 13648

To appear in: *Toxicology and Applied Pharmacology*

Received date: 20 January 2016
Revised date: 2 May 2016
Accepted date: 9 May 2016



Please cite this article as: Marmugi, Alice, Lukowicz, Céline, Lasserre, Frederic, Montagner, Alexandra, Polizzi, Arnaud, Ducheix, Simon, Goron, Adeline, Payrastra, Laurence, Gerbal-Chaloin, Sabine, Pascussi, Jean Marc, Moldes, Marthe, Pineau, Thierry, Guillou, Hervé, Mselli-Lakhal, Laila, Activation of the Constitutive Androstane Receptor induces hepatic lipogenesis and regulates *Pnpla3* gene expression in a LXR-independent way, *Toxicology and Applied Pharmacology* (2016), doi: [10.1016/j.taap.2016.05.006](https://doi.org/10.1016/j.taap.2016.05.006)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Comment citer ce document :

Marmugi, A., Lukowicz, C., Lasserre, F., Montagner, A., Polizzi, A., Ducheix, S., Goron, A., Payrastra, L., Gerbal-Chaloin, S., Pascussi, J. M., Moldes, M., Pineau, T., Guillou, H., Lakhal, L. (Auteur de correspondance) (2016). Activation of the constitutive androstane receptor induces hepatic lipogenesis and regulates *Pnpla3* gene expression in a LXR-independent way. *Toxicology*

Activation of the Constitutive Androstane Receptor induces hepatic lipogenesis and regulates *Pnpla3* gene expression in a LXR-independent way.

Alice Marmugi^{1,2,#}, Céline Lukowicz^{1,2,#}, Frederic Lasserre^{1,2}, Alexandra Montagner^{1,2}, Arnaud Polizzi^{1,2}, Simon Ducheix^{1,2}, Adeline Goron^{1,2}, Laurence Payraastre^{1,2}, Sabine Gerbal-Chaloin³, Jean Marc Pascussi⁴, Marthe Moldes^{5,6}, Thierry Pineau^{1,2}, Hervé Guillou^{1,2}, Laila Mselli-Lakhal^{1,2,*}.

¹ INRA; TOXALIM (Research Centre in Food Toxicology), Toulouse, France; ² Université de Toulouse; INP; UPS; TOXALIM, Toulouse, France ; ³ Institute of Regenerative Medicine and Biotherapy , INSERM U1183, Montpellier, France; ⁴ Centre National de la Recherche Scientifique, UMR5203, Institut de Génomique Fonctionnelle, Montpellier, France ; ⁵ Centre de Recherche Saint-Antoine, INSERM, UMR 938, Sorbonne Universités, Université Paris 6, Paris, France ; ⁶ Institut Hospitalo-Universitaire ICAN, Paris, France .

[#]Both authors contributed equally to this work.

*** Correspondence to:**

Dr Laila Mselli-Lakhal, ToxAlim UMR1331 INRA/INPT/UPS, Integrative Toxicology & Metabolism group, 180 chemin de Tournefeuille, BP 93173, 31027 Toulouse Cedex 3, FRANCE. Tel: +33 561285153. Fax: +33 561285310. laila.lakhal@toulouse.inra.fr

Abbreviations: CAR, constitutive androstane receptor; ChREBP, Carbohydrate Responsive Element-binding protein; CYP2B10, cytochrome P450, family 2, subfamily B, polypeptide 10; CYP2C29, cytochrome P450, family 2, subfamily C, polypeptide 29; CYP3A11, cytochrome P450, family 3, subfamily A, polypeptide 11; ELOV6, Elongation of long-chain fatty acids family member 6; FASN, Fatty acid synthase; GCK, glucokinase; GPAT, glycerol-

3-phosphate acyltransferase; LPK, L-type pyruvate kinase; LXR, Liver X receptor; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; PEPCK, phosphoenolpyruvate carboxykinase 1; PNPLA3, patatin-like phospholipase domain-containing protein 3; TCPOBOP, 1,4-bis[2-(3,5-dichloropyridyloxy)] benzene; PB, Phenobarbital ; SCD1, Stearoyl-CoA desaturase-1; SREBP1c, sterol regulatory element binding protein1c; TBP, TATA-box binding protein; THRSP-SPOT14, Thyroid hormone responsive Spot14 homolog.

Conflict of interest: No conflict of interest.

Financial support: This work was supported by grants from the French National Research Agency (CES PerinaTox program and CRISALIS) and by the Région Midi-Pyrénées. Alice Marmugi and Céline Lukowicz are funded by grants from INRA Animal Health Department and the Région Midi-Pyrénées.

ABSTRACT

The Constitutive Androstane Receptor (CAR, NR1I3) has been newly described as a regulator of energy metabolism. A relevant number of studies using animal models of obesity suggest that CAR activation could be beneficial on the metabolic balance. However, this remains controversial and the underlying mechanisms are still unknown. This work aimed to investigate the effect of CAR activation on hepatic energy metabolism during physiological conditions, i.e. in mouse models not subjected to metabolic/nutritional stress. Gene expression profiling in the liver of CAR knockout and control mice on chow diet and treated with a CAR agonist highlighted CAR-mediated up-regulations of lipogenic genes, concomitant with neutral lipid accumulation. A strong CAR-mediated up-regulation of the patatin-like phospholipase domain-containing protein 3 (*Pnpla3*) was demonstrated. *Pnpla3* is a gene whose polymorphism is associated with the pathogenesis of nonalcoholic fatty liver diseases (NAFLD) development. This observation was confirmed in human hepatocytes treated with the antiepileptic drug and CAR activator, phenobarbital and in immortalized human hepatocytes treated with CITCO. Studying the molecular mechanisms controlling *Pnpla3* gene expression, we demonstrated that CAR does not act by a direct regulation of *Pnpla3* transcription or via the Liver X Receptor but may rather involve the transcription factor Carbohydrate Responsive Element-binding protein. These data provide new insights into the regulation by CAR of glycolytic and lipogenic genes and on pathogenesis of steatosis. This also raises the question concerning the impact of drugs and environmental contaminants in lipid-associated metabolic diseases.

Keywords: PNPLA3/Adiponutrin; Constitutive Androstane Receptor; Liver X Receptor; Lipogenesis; Non-alcoholic fatty liver disease.

1. INTRODUCTION

The Constitutive androstane receptor (CAR, NR1I3) was initially characterized as a xenosensor playing an important role in the transcriptional activation of multiple xenochemical metabolizing enzymes in response to drugs and endocrine-disruptive chemicals (1, 2). Recent studies have also linked CAR to lipid and glucide metabolism. Clinical studies demonstrated a link between the use of CAR-activating drugs and the occurrence of metabolic disruptions in patients. Long-term use of phenobarbital (PB), a CAR activator, as an antiepileptic drug, induced a change in plasma lipid profiles of patients (3-5) and chronic treatment with other CAR activators like valproic acid or tamoxifen were associated with the occurrence of hepatic disorders (6, 7).

The role of CAR in the repression of genes involved in gluconeogenesis and β -oxidation was clearly established while its role in lipogenesis remains controversial. Hepatic gluconeogenesis regulatory enzymes phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) were reported to be repressed by CAR in several studies (8-12). It was suggested that CAR inhibits gluconeogenic genes through a competition with the hepatocyte nuclear factor 4 (HNF4) for binding in direct repeat 1 (DR1) motif in the promoter of gluconeogenic genes (8). It was also proposed that this inhibition was through interaction with the forkhead box protein O1 (FOXO1) to prevent its fixation in the insulin response sequence in gluconeogenic genes (13) or by facilitating the ubiquitination and degradation of PGC1 α (14). Inhibition of genes like cytochrome P450 4A14 (*Cyp4a14*), enoyl-CoA isomerase (*Eci*), carnitine palmitoyltransferase 1A (*CPT1a*) and cytosolic acyl-CoA thioesterase (*Cte*), involved in β -oxidation process is well established (15-17). It was supposed to occur through interaction with the peroxisome proliferator-activated receptor α (PPAR α), which is the major regulator of fatty acid metabolism (17). The role of CAR in the regulation of lipogenesis is more controversial, some studies reporting CAR as an "anti-

obesogenic" factor (18-20) and others as a "pro-lipogenic factor" (15, 21, 22). In leptin-deficient (ob/ob) or high fat fed mice CAR activation was shown to alleviate hepatic steatosis by repressing lipogenic genes like the stearoyl-CoA desaturase-1 (*Scd1*), sterol regulatory element-binding protein 1c (*Srebp-1c*) and the acetyl-CoA carboxylase (*Acc*) (18, 23). It was suggested that CAR inhibited lipogenesis through an interaction with Insig-1 a protein blocking the proteolytic activation of SREBP-1c (24). But some other studies reported on an up-regulation of lipogenic genes by CAR on human hepatocytes likely through a nonclassical S14 pathway (21). The effect of CAR activation on non-alcoholic steatohepatitis (NASH) pathogenesis in NASH-induced dietary mouse models was also subject to controversy (25, 26).

To our knowledge, there is no study investigating the effect of CAR activation on lipogenic gene expression and on the development of steatosis in physiological conditions, i.e. in mouse models not subjected to metabolic/nutritional stress and without pre-established disease. This is what we sought to evaluate in this study. In these conditions, CAR was identified as an enhancer of hepatic *de novo* lipogenesis and glycolysis through a Liver X Receptor (LXR)-independent pathway. Concomitantly, CAR activation resulted in hepatic lipid accumulation. We also demonstrated for the first time that CAR is a new player in the patatin-like phospholipase domain-containing protein 3 (*Pnpla3*) regulation, a gene whose polymorphism (I148M) in human represents a strong modifier of NAFLD severity and progression (27, 28).

2. MATERIAL AND METHODS

2.1. Chemicals.

Culture media and additives were purchased from Gibco-Life technologies (Saint Aubin, France). The 1,4-Bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP), dimethyl sulfoxide

(DMSO), phenobarbital (PB) and 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime (CITCO) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Williams E medium, fetal calf serum (FCS), insulin, glutamine and dexamethasone were purchased from Sigma-Aldrich (St. Quentin Fallavier, France).

2.2. Animals and treatment.

All *in vivo* experiments were conducted following French national and European laws and regulations relating to the housing and use of animals in research and were approved by an independent ethic committee (Toxcométique, INRA ToxAlim, Toulouse, France). This study employed CAR knockout mice (CAR^{-/-}; 10-11-week-old) back-crossed to C57BL/6J, as described in Wei et al. (29), and aged-matched C57BL/6J wild-type (WT) counterparts (Charles River, Les Oncins, France; one week acclimatization) as well as, LXR $\alpha\beta$ double-deficient mice (LXR^{-/-}; 12-week-old)—from a C57BL/6J x 129/SvJ mixed genetic background and littermate controls (30). CAR^{-/-} mice were provided by Dr. Urs A. Meyer (Biocenter, University Basel, Switzerland) and LXR^{-/-} mice were provided by Dr David J. Mangelsdorf (Howard Hughes Medical Institute, Dallas, TX). For short-term treatment, male and/or female mice ($n=6$ /group) were injected intraperitoneally (i.p.) once-daily during three days with either corn oil (vehicle) or TCPOBOP (3 mg/kg of body weight) dissolved in corn oil. For chronic treatment, male mice ($n=6$ /group) were injected once-weekly with TCPOBOP (3mg/kg of body weight; i.p. injection) during seven consecutive weeks using corn oil as vehicle. Mice were housed at INRA's transgenic rodent facility (ToxAlim, Toulouse, France) in a pathogen-free room under a standard 12-h light, 12-h dark cycle and fed a standard chow diet (SAFE Diet A04, Augy, France) with *ad libitum* drinking water.

2.3. Blood and organ sampling.

Blood was collected at the submandibular vein in EDTA-coated capillaries as described in (31). Plasma was prepared by centrifugation (2,000g; 10 minutes) and kept at -80°C until use. Following euthanasia by cervical dislocation (fed state), the liver and pWAT were removed, weighed, dissected, snap-frozen in liquid nitrogen, and stored at -80°C until use.

2.4. Biochemical Assays.

Hepatic lipid content was quantified as described in (32). Plasma levels of triglycerides and glucose were determined on a biochemical analyzer, COBAS-MIRA+ (Roche Diagnostics; Anexplo Service Phénotypage, Toulouse, France). Plasma insulin was assayed with the ultrasensitive mouse insulin enzyme-linked immunosorbent assay (ELISA) kit (Crystal Chem, Downers Grove, IL, USA).

2.5. Histology.

Frozen liver samples were embedded in Neg50 (Fisher Scientific, Courtaboeuf, France). Sections (5 µm, Leica RM2145 microtome, Nanterre, France) were stained with Oil-Red-O and hematoxylin/eosin and visualized with a Leica DFC300 camera (Leica Microsystems, Nanterre, France).

2.6. Cell culture experiments.

HepG2 human hepatoma cells and JWZ murine hepatic cells, also known as MuSH immortalized hepatocytes (33), and kindly provided by Joshua P. Gray (Center for Molecular Toxicology and Carcinogenesis, Pennsylvania State University, University Park, Pennsylvania, USA), were grown in DMEM supplemented with L-glutamine (2 mM), penicillin (100 IU/ml), streptomycin (100 µg/ml), and 10% fetal bovine serum (FBS). The culture medium of JWZ cells was supplemented with dexamethasone (1 µM). To allow CAR overexpression, HepG2 and JWZ cells were transfected with either pCR3-hCAR (HepG2) /

pCR3-mCAR (JWZ) plasmid, or pCR3-empty plasmid using lipofectamine 2000 (Invitrogen, Cergy Pontoise, France) according to the manufacturer's protocol. Following 48 h of transfection, cells were harvested with Trizol® (Invitrogen, Cergy Pontoise, France) before RNA extraction.

Immortalized human hepatocytes (IHH, (34)) were cultured in Williams E medium containing 11 mM glucose and supplemented with 10% FCS, 100U/ml penicillin, 100µg/ml streptomycin, 120 nM insulin, 2% glutamine and 50nM dexamethasone. Cells were then exposed to DMSO 1% or CITCO 1 µM (1% DMSO) in the same cell culture media containing 4% FCS instead of 10%. Following 48h of treatment, cells were harvested with Trizol® (Invitrogen, Cergy Pontoise, France) before RNA extraction.

2.7. Luciferase reporter gene assay.

JWZ cells were co-transfected either with a 3.3 kb Pnpla3 promoter construct cloned into a pGL3-basic vector, or the (NR1)₅-tk-luc pGL3 construct, or a pGL3-empty vector (0.5 µg), and with the pRL-TK plasmid (25 ng), and either with pCR3-mCAR or pCR3-empty (0.5 µg), using Lipofectamine 2000. The Pnpla3 promoter construct and (NR1)₅-tk-luc pGL3 construct were a gift from Dr Marthe Moldes (Centre de Recherche Saint-Antoine, INSERM, UMR 938, Université Paris 6, Paris, France) (35) and Dr Masahiko Negishi (Reproductive & Developmental Biology Laboratory / Pharmacogenetics Group, Research Triangle Park, North Carolina, USA), respectively. After 48 hours exposure, cells were lysed in cell culture lysis reagent (Promega, Madison, USA). Luciferase activities were determined according to the manufacturer's instruction (Dual-Luciferase® Reporter (DLR™) Assay System, Promega). Lysate samples were assayed in triplicate from four independent experiments. The firefly luciferase activity of each sample was normalized to Renilla luciferase activities.

2.8. Gene expression studies.

Total RNA was extracted with Trizol® reagent. Transcriptomic profiles were obtained by quantitative real-time polymerase chain reaction (RT-qPCR) as described in (32). Primers for SYBR Green assays are presented in Table 1. qPCR data were normalized by TATA-box binding protein (TBP) for mouse messenger RNA (mRNA) levels or β -actin/*PSMB6* for human messenger RNA (mRNA) levels as indicated in figure legends and raw data were analyzed with LinRegPCR (36).

2.9. Immunoblot Analysis. Nuclear protein extracts were prepared using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientific), according to the manufacturer's instructions. Following separation by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), nuclear protein extracts were probed with primary antibodies from Cell Signaling Technology (LAMIN A/C: 2032; Danvers, MA, USA), Novus Biological (CHREBP: nb400-135; Littleton, CO, USA), and secondary antibodies from Biotium (CF680 or CF770-labeled; Hayward, CA, USA). Band intensities were normalized to those of LAMIN A/C. The images were analyzed on the Odyssey Infrared Imaging system (Li-Cor, Lincoln, NE, USA).

2.10. Primary Culture of Human and Mouse Hepatocytes.

Liver samples were obtained from liver resections performed in adult patients for medical reasons unrelated to our research program. The use of human specimens for scientific purposes was approved by the French National Ethics Committee. Written or oral informed consent was obtained from each patient or family prior to surgery. The clinical characteristics of the liver donors are presented in Table 2. Primary human hepatocytes were prepared and cultured as described previously (37) and were either treated with 500 μ M phenobarbital (PB) dissolved in 0.1% DMSO for 24 hours or untreated (0.1% DMSO). Mouse hepatocytes were

prepared as described previously (38) and cultured in the presence of TCPOBOP (250 μ M in 0.1% DMSO; 24h) or DMSO (0.1%).

2.11. Statistical analysis.

All the data were analyzed using GraphPad Prism 7.0. Significance was assessed by appropriate unpaired Two-tailed Student's t-tests or two-way ANOVA followed by Tukey's multiple comparison *post hoc* test as indicated. $P^* < 0.05$ was considered significant.

3. RESULTS

3.1. Short-term CAR activation by TCPOBOP induces hepatic expression of genes related to lipid biosynthesis.

To investigate the effect of CAR activation on hepatic energy metabolism in healthy mice, CAR^{-/-} and controls (WT) male mice on chow diet were treated with either corn oil (vehicle) or a CAR-specific ligand, TCPOBOP at 3 mg/kg/day, a dose previously used to investigate the effect of CAR activation on hepatic lipid metabolism (39-41). The hepatic mRNA expression of the prototypical CAR target genes (*Cyp2b10*, *Cyp2c29* and *Cyp3a11*) was induced by TCPOBOP in WT mice but not in CAR^{-/-} mice (Figure 1A). Furthermore, CAR activation in WT mice induces a down-regulation of *Pepck* gene expression, while the expression of both glucokinase (*Gck*) and L-type pyruvate kinase (*Lpk*), which catalyse the first and the final step of glycolysis pathway respectively, was increased (Figure 1B). Moreover CAR activation induced an upregulation of lipogenic genes such as the fatty acid synthase (*Fasn*), elongation of long-chain fatty acids family member 6 (*Elovl6*), and glycerol-3-phosphate acyltransferase (*Gpat*), which incorporates newly synthesized fatty acids into triacylglycerol. The thyroid hormone responsive Spot14 homolog (*Thrsp-Spot14*), which encodes a protein regulating *de novo* lipogenesis through a molecular mechanism still undefined was also upregulated (Figure 1C). However, the hepatic mRNA expression of all

these genes was unaffected in TCPOBOP-treated CAR^{-/-} male mice (Figure 2), highlighting a CAR-dependent regulation of the glycolytic-lipogenic pathway. No sexual dimorphism was observed in WT mice. Indeed similar gene expression profiles were observed in the liver of TCPOBOP-treated WT females and males compared to their respective vehicle-treated counterparts (Sup Figure 1). However, some genes were slightly but significantly induced in TCPOBOP treated CAR^{-/-} females suggesting the activation of other pathways in this particular context (Sup Figure 1).

The coordination of lipid metabolism in white adipose tissue and in liver is important for whole-body metabolic homoeostasis. Measuring expression of lipogenic genes (*Ssd1*, *Elovl6*, *Gpat*) in adipose tissue showed no induction of expression in this tissue (Sup Figure 2).

3.3. Short-term CAR activation by TCPOBOP upregulates *Pnpla3* and *Pnpla5* expression.

Pnpla3 gene polymorphism has emerged as a new marker of human hepatic steatosis (27). Initially discovered in the adipose tissue, PNPLA3 is highly regulated by changes in energy balance (35, 42, 43). In the present study, CAR activation by TCPOBOP induced a strong increase in *Pnpla3* expression (Figure 1D). This was fully abrogated in TCPOBOP-treated CAR^{-/-} males and remained slightly increase in counterpart females (Figure 1D; Sup Figure 1). *Pnpla5* is located immediately upstream of the *Pnpla3* gene and exhibits both lipase and transacylase activities *in vitro* (44). In this study, *Pnpla5* gene expression pattern was similar to the one observed for *Pnpla3* (Figure 1D), whereas the expression of the triglyceride lipase *Pnpla2* did not differ between groups (Figure 1D).

3.4. Short-term CAR activation by TCPOBOP increases hepatic lipid accumulation.

We next assessed whether the increased expression of lipogenic genes was correlated with changes in hepatic neutral content. Hepatic neutral lipids were first stained with Oil-Red-O. The representative pictures in Figure 2 illustrate that the number and size of lipid droplets were increased by TCPOBOP treatment in WT mouse liver (Figure 2A, top panels), but did not change in the liver of CAR^{-/-} mice (Figure 2A, bottom panels). Surprisingly we observed a greater accumulation of lipids in the liver of vehicle-treated CAR^{-/-} mice compared to vehicle-treated WT mice (Figure 2A, left panels). Quantification of the liver lipid content by gas chromatography confirmed these observations. TCPOBOP treatment in WT mice did not affect the level of total hepatic cholesterol (data not shown), but hepatic cholesterol esters and triglycerides were significantly increased compared to vehicle treatment (Figure 2B). These changes were associated with a significant increase in liver weight (Table 3). However, in CAR^{-/-} mice hepatic lipid content and liver weight were unchanged in response to TCPOBOP (Figure 2B, Table 3). Finally, plasma triglyceride and glucose levels were decreased following TCPOBOP-treatment in WT mice but unchanged in CAR^{-/-} mice, and basal levels of both parameters were higher in vehicle-treated CAR^{-/-} mice compared to WT (Table 3).

3.5. *Pnpla3* promoter activity is not directly regulated by CAR.

To further explore the underlying mechanisms behind CAR's actions, we performed *in silico* analysis which revealed the presence of a CAR-DR4 (Direct Repeat 4) responsive element 2740 bp upstream of the ATG start codon of *Pnpla3* mouse promoter (Sup Table 1). We next determined whether the effect of CAR activation on *Pnpla3* expression was transcriptionally mediated. As shown in Figure 3, a reporter luciferase construct containing the mouse *Pnpla3* promoter (-3300 nt upstream of the luciferase ORF) (35) was co-transfected into JWZ cells with either a vector expressing mCAR (pCR3-mCAR), or a control vector (pCR3-empty). Additionally, a construct containing five copies of the optimal CAR

monomer binding motif (DR4-type NR1 sequence) upstream of the *tk-luciferase* promoter was used as a positive control. As expected, luciferase activity of the control ((NR1)₅-tk-luc-pGL3) was 22-fold increased upon mCAR overexpression (Figure 3A) while no significant change was observed for the construct containing the *Pnpla3* promoter (Figure 3B). Altogether, our data suggest that CAR does not directly regulate *Pnpla3* gene transcription.

3.6. LXR is not required for TCPOBOP-induced response of lipogenic genes.

Since LXR α and LXR β are important transcriptional regulators of lipogenesis (45), we next assessed whether LXR α/β could mediate CAR's actions. We treated LXR α/β double-deficient (LXR α/β ^{-/-}) mice and control mice with the CAR-specific ligand, TCPOBOP, or corn oil (vehicle), as performed previously. In WT mice, TCPOBOP induces a markedly increased hepatic mRNA expression of the prototypical CAR target gene *Cyp2b10* (Figure 4A). Similarly, the expression of the glycolytic enzymes (*Gck*, *Lpk*) and lipogenic enzymes (*Fasn*, *Elovl6*, *Thrsp-Spot14* and *Pnpla3*) was upregulated (Figure 4B-4C). These results suggest that TCPOBOP-mediated activation of CAR-target genes, including *Pnpla3*, is independent of LXR pathway.

3.7. CAR activation by TCPOBOP regulates ChREBP mRNA and protein levels.

The transcription factors Carbohydrate-responsive element-binding protein (ChREBP) and sterol regulatory element-binding protein 1c (SREBP1c) play a pivotal role in the liver by regulating glycolysis and lipogenesis (46). Furthermore PNPLA3 expression is under their direct transcriptional control (35). Thus we investigated whether these factors could be involved in the CAR-mediated activation of lipogenic genes and lipid accumulation.

In adipocytes, ChREBP α isoform is likely responsible for inducing ChREBP β which is transcribed from an alternative promoter (47). In this study, the mRNA expression of both

isoforms was significantly induced in response to TCPOBOP in WT mice but unchanged in CAR^{-/-} mice, although a larger variability was observed for *Chrebpβ* (Figure 5A). In addition the mRNA expression of *Srebp1c* was unchanged in response to TCPOBOP in WT and CAR^{-/-} mice (Figure 5B).

Since the nuclear translocation of ChREBP is a critical step for activation of its target genes, the ChREBP subcellular localization in response to TCPOBOP was checked. In the liver of TCPOBOP-treated WT mice, an increase of nuclear ChREBP content was observed, but not in TCPOBOP-treated CAR^{-/-} mice (Figure 5C).

3.8. Chronic CAR activation by TCPOBOP induces hepatic expression of genes related to lipid biosynthesis and lipid accumulation in the liver.

To determine whether the observed effects are not the result of an acute response to CAR activation, CAR^{-/-} and controls (WT) male mice on chow diet were treated with either corn oil or TCPOBOP at 3 mg/kg/day once-weekly during seven consecutive weeks. As observed previously, CAR activation by TCPOBOP induced the up-regulation of the prototypical CAR target genes *Cyp2b10* and *Cyp3a11*, as well as a down-regulation of the *Pepck* and the overexpression of key lipogenic genes including *Pnpla3* (Figure 6A-C). However, the expression of the same genes was unchanged in TCPOBOP-treated CAR^{-/-} male mice (Figure 6A-C). The representative pictures in Figure 6D illustrate an accumulation of lipid droplets induced by TCPOBOP treatment in the liver of WT mice compared to those of vehicle-WT mice (Figure 6D). Chronic CAR activation also resulted in a greater accumulation of lipids in the liver of vehicle-treated CAR^{-/-} mice compared to vehicle-treated WT mice as observed previously after a short term exposure to TCPOBOP (Figure 2A).

3.9. CAR activation induces *Pnpla3* expression in human hepatocytes.

Pnpla3 gene regulation by CAR represents an original result never reported before. Thus we sought to determine whether the CAR-dependent induction of *pnp1a3* was also observed *in vitro*, particularly in human hepatocytes.

We first overexpressed CAR in human hepatoma HepG2 cells and murine hepatic cell lines using pCR3-hCAR (human CAR isoform) or pCR3-mCAR (murine CAR isoform) expression vector respectively. In these cell lines, both hCAR and mCAR proteins have been shown to be constitutively active (48). CAR overexpression resulted in significant inductions of the CAR target genes *CYP2B6/Cyp2b10* and *PNPLA3/Pnpla3* (Figure 7A and 7C). Furthermore, the mRNA expression of these genes was significantly induced in primary mouse hepatocytes treated 24h with TCPOBOP (250μM) compared to the control condition (DMSO) (Figure 7B). Similar results were obtained using primary human hepatocytes treated with the CAR-activator phenobarbital (PB; 500 μM; 24h), a barbiturate drug widely used to treat epilepsy (49). As shown in Figure 7D, hepatocytes from three of the four donors display an increase of *PNPLA3* expression correlated with inductions of *SCD1* in response to PB treatment. It is known that PB is an indirect CAR activator and is considered to be a mixed CAR/PXR activator. Consequently, immortalized human hepatocytes were treated with CITCO which is a well-characterized specific direct activator of human CAR (50). CAR activation by CITCO resulted in significant inductions of *CYP2B6*, as well as of the lipogenic genes *Fasn*, *Pnpla3* and an increase in the mRNA levels of *ChREBP* and *SREBP1c* (Figure 7E).

Overall, these results suggest a possible translation of the results obtained in mice to humans.

4. DISCUSSION

In the present study, we showed that CAR activation by TCPOBOP positively regulates genes involved in hepatic glycolysis as well as lipogenesis and induces steatosis in mouse

liver. We demonstrated for the first time that CAR regulates *Pnpla3* expression both in mouse liver and human hepatocytes. The subsequent study of the underpinning mechanisms highlighted that CAR does not act by a direct regulation of *Pnpla3* transcription or via the Liver X Receptor. We confirmed the previously reported inhibitory effect of CAR on gluconeogenesis through the repression of PEPCK (8-12). We measured the expression of a large panel of key genes regulating glycolysis and different steps of lipogenesis including fatty acid synthesis (*Fasn*), elongation (*Elovl6*) and esterification (*Gpat*) which had never been assayed before. We showed a clear synergic and CAR-dependent up-regulation of all these genes both in males and females. A slight induction of some genes in CAR $-/-$ female livers suggests the activation of other pathways in this particular context (*Cyp2b10*, *Cyp2c29*, *Pnpla3*; Sup Figure 1). These results are consistent with those reported by Breuker et al., highlighting a prolipogenic effect of CAR through the up-regulation of Thrsp-Spot14, a regulator of the lipogenic process, in human primary hepatocytes (21). It is unlikely that the upregulation of lipogenic genes and lipid accumulation are a consequence of acute response to TCPOBOP since longer exposure time to this chemical indicates similar results (Figure 6).

The Pregnane X receptor (PXR) is another xenosensor closely related to CAR. It is well established that CAR and PXR exhibit similar roles in the regulation of β -oxidation and gluconeogenesis but could display opposing actions on lipid homeostasis (51). Indeed PXR is considered as a pro-lipogenic receptor and has a putative role in the pathogenesis of steatohepatitis (52), whereas CAR was originally considered as displaying anti-lipogenic properties (53, 54). These assumptions were based on data from mouse models subjected to metabolic/nutritional stress (18, 23). In the present study, healthy mice on a standard chow diet were used. In these conditions, we identified CAR as an enhancer of hepatic *de novo* lipogenesis suggesting an identical role of CAR and PXR in the regulation of lipid metabolism. This assumption is supported by the regulation by CAR of *Pnpla3*, a gene whose

polymorphism has recently emerged as an important marker of liver steatosis (55). The rs738409 variant (encoding an amino acid substitution Ile148Met) of PNPLA3 is a strong modifier of the NAFLD etiology by increasing liver fat content and the disease severity and progression (27, 28, 56). As a lipogenic enzyme, *Pnpla3* was reported to be transcriptionally regulated by SREBP-1c, LXR and ChREBP in response to insulin and glucose respectively (35, 42, 43). Our major finding is that *Pnpla3* is also regulated by CAR. This regulation was confirmed in hepatocytes of human donors treated with the anti-epileptic and CAR activator, PB. It was also confirmed in human hepatocytes treated with CITCO which is a well-characterized specific direct activator of human CAR. These results suggest its relevance for human.

Little is known about the mechanisms underpinning the CAR-mediated regulation of lipogenic genes. Our results highlighted an indirect regulation of the mouse *Pnpla3* promoter by CAR. Since LXR is a central regulator of hepatic *de novo* lipogenesis, and could crosstalk with CAR (57), we next investigated its potential involvement. Gene-expression profiles were similar independently of the presence or absence of LXR, suggesting that the induction of lipogenic genes upon TCPOBOP treatment is not mediated by LXR. Underlying mechanisms of gene regulation by CAR of glycolytic and lipogenic genes are probably more complex and may involve one or more other transcription factors. Most of the genes we found up-regulated by CAR are known to be regulated by SREBP-1c, CHREBP or both (58). While further investigations are ongoing, the preliminary results presented in Figure 5 highlight that the transcription factor CHREBP could mediate the observed effects in mice and both factors might mediate CITCO-induced responses in immortalized human hepatocytes (Figure 7E).

CAR activation by TCPOBOP resulted in a hepatic lipid accumulation consisting in triglycerides and cholesterol esters. Thus, the results presented here are in contrast to those

showing that CAR activation alleviates hepatic steatosis (18, 23). We showed that this activation could instead have deleterious effects on mouse liver leading to aberrant hepatic *de novo* lipogenesis. The regulation by CAR of energy metabolism is probably more complex, and depends on the metabolic context. However, these results raise the question concerning the impact of drugs and environmental contaminants in lipid-associated metabolic diseases, such as obesity, insulin resistance, and related clinical disorders (type 2 diabetes and cardiovascular diseases), since most of them are CAR regulators. These risks could be particularly important in subjects carrying the PNPLA3 rs738409 C>G variant which could be more vulnerable.

Acknowledgments: We thank Prof. Dr. Urs A. Meyer (Biocenter, University Basel, Switzerland) for providing the CAR knockout mice and Dr D.J. Mangelsdorf (Howard Hughes Medical Institute, Dallas, TX) for providing us with LXR-deficient mice. We are very grateful to Colette Bétoulières (INRA Toxalim Toulouse, France) for animal care and technical assistance for animal experiments. We thank the staff members of the following GenoToul core facilities for technical assistance: MetaToul/Lipidomic, Anexplo/Histopathology and Phenotyping.

REFERENCES

1. Zhang, H., Zhang, Z., Nakanishi, T., Wan, Y., Hiromori, Y., Nagase, H., and Hu, J. 2015. Structure-dependent activity of phthalate esters and phthalate monoesters binding to human constitutive androstane receptor. *Chem Res Toxicol* 28:1196-1204.
2. Baldwin, W.S., and Roling, J.A. 2009. A concentration addition model for the activation of the constitutive androstane receptor by xenobiotic mixtures. *Toxicol Sci* 107:93-105.
3. Calandre, E.P., Rodriguez-Lopez, C., Blazquez, A., and Cano, D. 1991. Serum lipids, lipoproteins and apolipoproteins A and B in epileptic patients treated with valproic acid, carbamazepine or phenobarbital. *Acta Neurol Scand* 83:250-253.
4. Luoma, P.V., Myllyla, V.V., Sotaniemi, E.A., and Hokkanen, T.E. 1979. Plasma HDL cholesterol in epileptics with elevated triglyceride and cholesterol. *Acta Neurol Scand* 60:56-63.
5. Yamamoto, T., Takahashi, S., Nakaoko, H., Nakazato, M., Suda, M., Moriwaki, Y., Hada, T., Yanagisawa, M., and Higashino, K. 1989. The effect of phenobarbital on human plasma lipids. *Int J Clin Pharmacol Ther Toxicol* 27:463-466.
6. Bilici, A., Ozguroglu, M., Mihmanli, I., Turna, H., and Adaletli, I. 2007. A case-control study of non-alcoholic fatty liver disease in breast cancer. *Med Oncol* 24:367-371.
7. Verrotti, A., Agostinelli, S., Parisi, P., Chiarelli, F., and Coppola, G. 2011. Nonalcoholic fatty liver disease in adolescents receiving valproic acid. *Epilepsy Behav* 20:382-385.
8. Miao, J., Fang, S., Bae, Y., and Kemper, J.K. 2006. Functional inhibitory cross-talk between constitutive androstane receptor and hepatic nuclear factor-4 in hepatic

- lipid/glucose metabolism is mediated by competition for binding to the DR1 motif and to the common coactivators, GRIP-1 and PGC-1alpha. *J Biol Chem* 281:14537-14546.
9. Kachaylo, E.M., Yarushkin, A.A., and Pustyl'nyak, V.O. 2012. Constitutive androstane receptor activation by 2,4,6-triphenyldioxane-1,3 suppresses the expression of the gluconeogenic genes. *Eur J Pharmacol* 679:139-143.
 10. Yarushkin, A.A., Kachaylo, E.M., and Pustyl'nyak, V.O. 2013. The constitutive androstane receptor activator 4-[(4R,6R)-4,6-diphenyl-1,3-dioxan-2-yl]-N,N-dimethylaniline inhibits the gluconeogenic genes PEPCK and G6Pase through the suppression of HNF4alpha and FOXO1 transcriptional activity. *Br J Pharmacol* 168:1923-1932.
 11. Yu, L., Wang, Z., Huang, M., Li, Y., Zeng, K., Lei, J., Hu, H., Chen, B., Lu, J., Xie, W., et al. 2015. Evodia alkaloids suppress gluconeogenesis and lipogenesis by activating the constitutive androstane receptor. *Biochim Biophys Acta*.
 12. Ling, H.Y., Yao, Q.X., Qi, Z.Q., Yang, S.S., He, J.Q., Zhang, K.F., and Hu, B. 2014. [The role of arecoline on hepatic insulin resistance in type 2 diabetes rats]. *Zhongguo Ying Yong Sheng Li Xue Za Zhi* 30:208-212.
 13. Kodama, S., Koike, C., Negishi, M., and Yamamoto, Y. 2004. Nuclear receptors CAR and PXR cross talk with FOXO1 to regulate genes that encode drug-metabolizing and gluconeogenic enzymes. *Mol Cell Biol* 24:7931-7940.
 14. Gao, J., Yan, J., Xu, M., Ren, S., and Xie, W. 2015. CAR Suppresses Hepatic Gluconeogenesis by Facilitating the Ubiquitination and Degradation of PGC1alpha. *Mol Endocrinol* 29:1558-1570.
 15. Maglich, J.M., Lobe, D.C., and Moore, J.T. 2009. The nuclear receptor CAR (NR1I3) regulates serum triglyceride levels under conditions of metabolic stress. *J Lipid Res* 50:439-445.

16. Ueda, A., Hamadeh, H.K., Webb, H.K., Yamamoto, Y., Sueyoshi, T., Afshari, C.A., Lehmann, J.M., and Negishi, M. 2002. Diverse roles of the nuclear orphan receptor CAR in regulating hepatic genes in response to phenobarbital. *Mol Pharmacol* 61:1-6.
17. Kassam, A., Winrow, C.J., Fernandez-Rachubinski, F., Capone, J.P., and Rachubinski, R.A. 2000. The peroxisome proliferator response element of the gene encoding the peroxisomal beta-oxidation enzyme enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase is a target for constitutive androstane receptor beta/9-cis-retinoic acid receptor-mediated transactivation. *J Biol Chem* 275:4345-4350.
18. Dong, B., Saha, P.K., Huang, W., Chen, W., Abu-Elheiga, L.A., Wakil, S.J., Stevens, R.D., Ilkayeva, O., Newgard, C.B., Chan, L., et al. 2009. Activation of nuclear receptor CAR ameliorates diabetes and fatty liver disease. *Proc Natl Acad Sci U S A* 106:18831-18836.
19. Masuyama, H., and Hiramatsu, Y. 2012. Treatment with a constitutive androstane receptor ligand ameliorates the signs of preeclampsia in high-fat diet-induced obese pregnant mice. *Mol Cell Endocrinol* 348:120-127.
20. Masuyama, H., and Hiramatsu, Y. 2012. Treatment with constitutive androstane receptor ligand during pregnancy prevents insulin resistance in offspring from high-fat diet-induced obese pregnant mice. *Am J Physiol Endocrinol Metab* 303:E293-300.
21. Breuker, C., Moreau, A., Lakhal, L., Tamasi, V., Parmentier, Y., Meyer, U., Maurel, P., Lumbroso, S., Vilarem, M.J., and Pascussi, J.M. 2010. Hepatic expression of thyroid hormone-responsive spot 14 protein is regulated by constitutive androstane receptor (NR1I3). *Endocrinology* 151:1653-1661.
22. Maglich, J.M., Watson, J., McMillen, P.J., Goodwin, B., Willson, T.M., and Moore, J.T. 2004. The nuclear receptor CAR is a regulator of thyroid hormone metabolism during caloric restriction. *J Biol Chem* 279:19832-19838.

23. Gao, J., He, J., Zhai, Y., Wada, T., and Xie, W. 2009. The constitutive androstane receptor is an anti-obesity nuclear receptor that improves insulin sensitivity. *J Biol Chem* 284:25984-25992.
24. Roth, A., Looser, R., Kaufmann, M., and Meyer, U.A. 2008. Sterol regulatory element binding protein 1 interacts with pregnane X receptor and constitutive androstane receptor and represses their target genes. *Pharmacogenet Genomics* 18:325-337.
25. Yamazaki, Y., Kakizaki, S., Horiguchi, N., Sohara, N., Sato, K., Takagi, H., Mori, M., and Negishi, M. 2007. The role of the nuclear receptor constitutive androstane receptor in the pathogenesis of non-alcoholic steatohepatitis. *Gut* 56:565-574.
26. Baskin-Bey, E.S., Anan, A., Isomoto, H., Bronk, S.F., and Gores, G.J. 2007. Constitutive androstane receptor agonist, TCPOBOP, attenuates steatohepatitis in the methionine choline-deficient diet-fed mouse. *World J Gastroenterol* 13:5635-5641.
27. Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L.A., Boerwinkle, E., Cohen, J.C., and Hobbs, H.H. 2008. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. *Nat Genet* 40:1461-1465.
28. Dongiovanni, P., Donati, B., Fares, R., Lombardi, R., Mancina, R.M., Romeo, S., and Valenti, L. 2013. PNPLA3 I148M polymorphism and progressive liver disease. *World J Gastroenterol* 19:6969-6978.
29. Wei, P., Zhang, J., Egan-Hafley, M., Liang, S., and Moore, D.D. 2000. The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism. *Nature* 407:920-923.
30. Repa, J.J., Liang, G., Ou, J., Bashmakov, Y., Lobaccaro, J.M., Shimomura, I., Shan, B., Brown, M.S., Goldstein, J.L., and Mangelsdorf, D.J. 2000. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. *Genes Dev* 14:2819-2830.

31. Golde, W.T., Gollobin, P., and Rodriguez, L.L. 2005. A rapid, simple, and humane method for submandibular bleeding of mice using a lancet. *Lab Anim (NY)* 34:39-43.
32. Marmugi, A., Ducheix, S., Lasserre, F., Polizzi, A., Paris, A., Priymenko, N., Bertrand-Michel, J., Pineau, T., Guillou, H., Martin, P.G., et al. 2012. Low doses of bisphenol A induce gene expression related to lipid synthesis and trigger triglyceride accumulation in adult mouse liver. *Hepatology* 55:395-407.
33. Tien, E.S., Gray, J.P., Peters, J.M., and Vanden Heuvel, J.P. 2003. Comprehensive gene expression analysis of peroxisome proliferator-treated immortalized hepatocytes: identification of peroxisome proliferator-activated receptor alpha-dependent growth regulatory genes. *Cancer Res* 63:5767-5780.
34. Schippers, I.J., Moshage, H., Roelofsen, H., Muller, M., Heymans, H.S., Ruiters, M., and Kuipers, F. 1997. Immortalized human hepatocytes as a tool for the study of hepatocytic (de-)differentiation. *Cell Biol Toxicol* 13:375-386.
35. Dubuquoy, C., Robichon, C., Lasnier, F., Langlois, C., Dugail, I., Fougelle, F., Girard, J., Burnol, A.F., Postic, C., and Moldes, M. 2011. Distinct regulation of adiponutrin/PNPLA3 gene expression by the transcription factors ChREBP and SREBP1c in mouse and human hepatocytes. *J Hepatol* 55:145-153.
36. Ruijter, J.M., Ramakers, C., Hoogaars, W.M., Karlen, Y., Bakker, O., van den Hoff, M.J., and Moorman, A.F. 2009. Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data. *Nucleic Acids Res* 37:e45.
37. Pichard, L., Raulet, E., Fabre, G., Ferrini, J.B., Ourlin, J.C., and Maurel, P. 2006. Human hepatocyte culture. *Methods Mol Biol* 320:283-293.
38. Dentin, R., Pegorier, J.P., Benhamed, F., Fougelle, F., Ferre, P., Fauveau, V., Magnuson, M.A., Girard, J., and Postic, C. 2004. Hepatic glucokinase is required for

- the synergistic action of ChREBP and SREBP-1c on glycolytic and lipogenic gene expression. *J Biol Chem* 279:20314-20326.
39. Rezen, T., Tamasi, V., Lovgren-Sandblom, A., Bjorkhem, I., Meyer, U.A., and Rozman, D. 2009. Effect of CAR activation on selected metabolic pathways in normal and hyperlipidemic mouse livers. *BMC Genomics* 10:384.
 40. Zhai, Y., Wada, T., Zhang, B., Khadem, S., Ren, S., Kuruba, R., Li, S., and Xie, W. 2010. A functional cross-talk between liver X receptor-alpha and constitutive androstane receptor links lipogenesis and xenobiotic responses. *Mol Pharmacol* 78:666-674.
 41. Tojima, H., Kakizaki, S., Yamazaki, Y., Takizawa, D., Horiguchi, N., Sato, K., and Mori, M. 2012. Ligand dependent hepatic gene expression profiles of nuclear receptors CAR and PXR. *Toxicol Lett* 212:288-297.
 42. Qiao, A., Liang, J., Ke, Y., Li, C., Cui, Y., Shen, L., Zhang, H., Cui, A., Liu, X., Liu, C., et al. 2011. Mouse patatin-like phospholipase domain-containing 3 influences systemic lipid and glucose homeostasis. *Hepatology* 54:509-521.
 43. Huang, Y., He, S., Li, J.Z., Seo, Y.K., Osborne, T.F., Cohen, J.C., and Hobbs, H.H. 2010. A feed-forward loop amplifies nutritional regulation of PNPLA3. *Proc Natl Acad Sci U S A* 107:7892-7897.
 44. Lake, A.C., Sun, Y., Li, J.L., Kim, J.E., Johnson, J.W., Li, D., Revett, T., Shih, H.H., Liu, W., Paulsen, J.E., et al. 2005. Expression, regulation, and triglyceride hydrolase activity of Adiponutrin family members. *J Lipid Res* 46:2477-2487.
 45. Mitro, N., Mak, P.A., Vargas, L., Godio, C., Hampton, E., Molteni, V., Kreusch, A., and Saez, E. 2007. The nuclear receptor LXR is a glucose sensor. *Nature* 445:219-223.

46. Xu, X., So, J.S., Park, J.G., and Lee, A.H. 2013. Transcriptional control of hepatic lipid metabolism by SREBP and ChREBP. *Semin Liver Dis* 33:301-311.
47. Herman, M.A., Peroni, O.D., Villoria, J., Schon, M.R., Abumrad, N.A., Bluher, M., Klein, S., and Kahn, B.B. 2012. A novel ChREBP isoform in adipose tissue regulates systemic glucose metabolism. *Nature* 484:333-338.
48. Yang, H., and Wang, H. 2014. Signaling control of the constitutive androstane receptor (CAR). *Protein Cell* 5:113-123.
49. Mutoh, S., Sobhany, M., Moore, R., Perera, L., Pedersen, L., Sueyoshi, T., and Negishi, M. 2013. Phenobarbital indirectly activates the constitutive active androstane receptor (CAR) by inhibition of epidermal growth factor receptor signaling. *Sci Signal* 6:ra31.
50. Maglich, J.M., Parks, D.J., Moore, L.B., Collins, J.L., Goodwin, B., Billin, A.N., Stoltz, C.A., Kliewer, S.A., Lambert, M.H., Willson, T.M., et al. 2003. Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes. *J Biol Chem* 278:17277-17283.
51. Konno, Y., Negishi, M., and Kodama, S. 2008. The roles of nuclear receptors CAR and PXR in hepatic energy metabolism. *Drug Metab Pharmacokinet* 23:8-13.
52. Bitter, A., Rummele, P., Klein, K., Kandel, B.A., Rieger, J.K., Nussler, A.K., Zanger, U.M., Trauner, M., Schwab, M., and Burk, O. 2015. Pregnane X receptor activation and silencing promote steatosis of human hepatic cells by distinct lipogenic mechanisms. *Arch Toxicol* 89:2089-2103.
53. Gao, J., and Xie, W. 2010. Pregnane X receptor and constitutive androstane receptor at the crossroads of drug metabolism and energy metabolism. *Drug Metab Dispos* 38:2091-2095.

54. Wada, T., Gao, J., and Xie, W. 2009. PXR and CAR in energy metabolism. *Trends Endocrinol Metab* 20:273-279.
55. Dongiovanni, P., and Valenti, L. 2015. Genetics of nonalcoholic fatty liver disease. *Metabolism*.
56. Smagris, E., BasuRay, S., Li, J., Huang, Y., Lai, K.M., Gromada, J., Cohen, J.C., and Hobbs, H.H. 2015. Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. *Hepatology* 61:108-118.
57. Xiao, L., Xie, X., and Zhai, Y. 2010. Functional crosstalk of CAR-LXR and ROR-LXR in drug metabolism and lipid metabolism. *Adv Drug Deliv Rev* 62:1316-1321.
58. Postic, C., and Girard, J. 2008. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. *J Clin Invest* 118:829-838.

TABLE LEGENDS

Table 1. Oligonucleotide sequences for real time PCR.

Table 2. Clinical characteristics of the liver donors. F = female; M = male; PHH = primary human hepatocyte; Age in years.

Table 3. Body weight, relative liver weight and plasma parameters of WT and CAR^{-/-} mice (n=6 males) treated with either vehicle (corn oil) or TCPOBOP (3 mg/kg/day) for 3 days. The statistical significance was evaluated using two-way ANOVA followed by *Tukey's post hoc test* (a: significant treatment effect, TCPOBOP vs vehicle; b, significant genotype effect, CAR^{-/-} vs WT; p<0.05). Values are mean ± SEM.

FIGURE LEGENDS

Figure 1. CAR regulates the expression of key genes involved in hepatic glucose metabolism and *de novo* lipogenesis. Hepatic mRNAs from wild-type (WT) and CAR null (CAR^{-/-}) male mice (*n* = 6 mice per group) treated with either corn oil (vehicle) or the CAR agonist, TCPOBOP (3 mg/kg/day) for three days were used to assay by RT-qPCR the relative expression of (A) Cytochrome P450 enzymes (*Cyp2b10*, *Cyp2c29*, *Cyp3a11*), and genes involved in (B) glucose metabolism (*Pepck*, *Gck*, and, *Lpk*), (C) *de novo* lipogenesis (*Fasn*, *Elov6*, *Gpat*, *Thrsp-Spot14*) and (D) PNPLA family members (*Pnpla3*, 5, 2). Data were normalized to TBP mRNA expression levels and to the vehicle-treated mice for each genotype. Statistical significance was evaluated using the unpaired Two-tailed Student's *t* test. Values shown are the mean ± SEM. Asterisk denotes a significant difference compared with control condition of each genotype: *P<0.05; **P<0.01; ***P<0.001.

Figure 2. CAR activation by TCPOBOP increases hepatic triglycerides and cholesterol esters levels. (A) Oil-red O-staining of neutral lipids performed on histological sections of livers from WT and CAR^{-/-} mice treated for three days with either corn oil (vehicle) or the CAR agonist, TCPOBOP (3 mg/kg/day). Neutral lipids appear in red (original magnification x200). (B) Neutral lipids were extracted from the liver of the same animals. After extraction, lipids were analyzed by gas chromatography. The presence of internal standards enabled to quantify the neutral lipids. Statistical significance was evaluated using two-way ANOVA followed by *Tukey's post hoc test*. Asterisk denotes a significant difference compared with control condition for each genotype: **P<0.01; ***P<0.001.

Figure 3. Pnpla3 promoter activity is not directly regulated by CAR. Luciferase assays were performed in JWZ cells transiently co-transfected with either a pCR3-mCAR vector expressing mCAR (mCAR) or with a control pCR3-empty vector (mCAR), and with (A) a construct containing five copies of the optimal CAR monomer binding motif (DR4-type NR1 sequence) in front of the *tk-luciferase* promoter ((NR1)₅-tk-luc), or (B) with a reporter containing the mouse Pnpla3 promoter (-3300nt upstream of the luciferase ORF). The pGL3-empty basic vector was used as negative control. Firefly luciferase activity of each sample was normalized to Renilla luciferase activity. Results are expressed as mean ± SEM from four independent experiments. Statistical significance was evaluated using two-way ANOVA followed by *Tukey's post hoc test*. *P<0.05; **P<0.01; ***P<0.001.

Figure 4. TCPOCOP-induced up-regulation of lipogenic genes is not mediated by LXRαβ. Hepatic mRNAs from wild-type (WT) and LXR null (LXR^{-/-}) male mice (*n* = 6 mice per group) treated with either corn oil (vehicle) or the CAR agonist, TCPOBOP (3

mg/kg/day) for three days were used to assay by RT-qPCR the relative expression of (A) the prototypical CAR target gene *Cyp2b10*, and the relative expression of genes involved in (B) glucose metabolism (*Gck*, *Lpk*), and in (C) *de novo* lipogenesis (*Fasn*, *Elov6*, *Thrsp-Spot14*, and *Pnpla3*). Data were normalized to TBP mRNA expression levels and to the vehicle-treated mice for each genotype. Statistical significance was evaluated using the unpaired Two-tailed Student's t test. Values shown are the mean \pm SEM. Asterisk denotes a significant difference compared with control condition of each genotype: **P<0.01; ***P<0.001.

Figure 5. CAR activation by TCPOBOP increased *Chrebp* mRNA expression and nuclear ChREBP content. (A) Quantification of *Chrebp* α and β and *Srebp1c* mRNA levels by RT-qPCR from WT and CAR^{-/-} male mice ($n = 6$ mice per group) treated with either corn oil (vehicle) or the CAR agonist, TCPOBOP (3 mg/kg/day) for three days. Values shown are the mean \pm SEM. Data were normalized to TBP mRNA expression levels and to the vehicle-treated mice for each genotype. Statistical significance was evaluated using the unpaired Two-tailed Student's t test. (C) Representative western blot images and quantification of nuclear ChREBP (ChREBPn) content in liver extracts ($n = 2$ mice per group). LAMIN A/C antibody was used as loading controls. Values shown are the mean \pm SEM. The Statistical significance was evaluated using two-way ANOVA followed by *Tukey's post hoc test*. Asterisk denotes a significant difference compared with control condition: *P<0.05; **P<0.01.

Figure 6. Chronic activation of CAR regulates the expression of key genes involved in hepatic glucose metabolism and *de novo* lipogenesis and leads to hepatic triglycerides accumulation. Hepatic mRNAs from wild-type (WT) and CAR null (CAR^{-/-}) male mice ($n = 6$ mice per group) treated with either corn oil (vehicle) or the CAR agonist, TCPOBOP (single

ip injection of 3 mg/kg/week) for seven weeks were used to assay by RT-qPCR the relative expression of (A) Cytochrome P450 (*Cyp2b10*, *Cyp2c29*), and genes involved in (B) glucose metabolism (*Pepck*, *Lpk*), (C) *de novo* lipogenesis (*Fasn*, *Elovl6*, *Thrsp-Spot 14* and *Pnpla3*). Data were normalized to TBP mRNA expression levels and to the vehicle-treated mice for each genotype. Statistical significance was evaluated using the unpaired Two-tailed Student's t test. (D) Oil-red O-staining of neutral lipids performed on histological sections of livers from the same animals. Neutral lipids appear in red (original magnification x200). Asterisk denotes a significant difference compared with control condition for each genotype: **P<0.01; *** P<0.001

Figure 7. CAR activation induces *Cyp2b10/CYP2B6* and *Pnpla3/PNPLA3* gene expression *in vitro*. The hepatic mRNA levels of *Cyp2b10* and *Pnpla3* were examined by RT-qPCR in (A) JWZ cell lines transfected either with a vector expressing mCAR or a control vector (-) and, in (B) primary mouse hepatocytes treated for 24 hours with TCPOBOP (0.1% DMSO) or 0.1% DMSO (control). The data were normalized to TBP mRNA expression levels. (C) The hepatic mRNA levels of *CYP2B6* and *PNPLA3* were examined by RT-qPCR in HepG2 cell lines transfected either with a vector expressing hCAR or a control vector (-). (D) Cultured hepatocytes from four donors were exposed to phenobarbital (PB; 500 μ M) or DMSO (control) for 24 hrs. The hepatic mRNA levels of *CYPBB6*, *PNPLA3* and *SCD1* were examined by RT-qPCR and normalized to β -actin mRNA expression levels (HepG2/human hepatocytes). (E) Immortalized human hepatocytes (IHH) were treated for 48 hours with CITCO (1 μ M) or DMSO (control). The hepatic mRNA levels of *CYP2B6*, *LPK*, *ACC*, *PNPLA3*, *ChREBP* and *SREBP1c* were examined by RT-qPCR and normalized to *PSMB6* mRNA expression levels. All the data were analyzed by Two-tailed Student's t-test.

Asterisk denotes a significant difference compared with the control condition: * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$.

Sup Figure 1. CAR regulates the expression of key genes involved in hepatic glucose metabolism and *de novo* lipogenesis in females. Hepatic mRNAs from wild-type (WT) and CAR null (CAR^{-/-}) male mice ($n = 6$ mice per group) treated with either corn oil (vehicle) or the CAR agonist, TCPOBOP (3 mg/kg/day) for three days were used to assay by RT-qPCR the relative expression of (A) Cytochrome P450 enzymes (*Cyp2b10*, *Cyp2c29*, *Cyp3a11*), and genes involved in (B) glucose metabolism (*Pepck*, *Gck*, and, *Lpk*), and (C) *de novo* lipogenesis (*Pnpla3*, *Thrsp-Spot14*). Data were normalized to TBP mRNA expression levels and to the vehicle-treated mice for each genotype. Statistical significance was evaluated using the unpaired Two-tailed Student's t test. Values shown are the mean \pm SEM. Asterisk denotes a significant difference compared with control condition of each genotype: * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$.

Sup Figure 2. CAR activation does not regulate the expression of key genes involved in *de novo* lipogenesis in white adipose tissues. mRNA levels in perigonadal white adipose tissues from wild-type (WT) and CAR null (CAR^{-/-}) male mice ($n = 6$ mice per group) treated with either corn oil (vehicle) or the CAR agonist, TCPOBOP (3 mg/kg/day) for three days were used to assay by RT-qPCR the relative expression of genes encoding *de novo* lipogenesis enzymes (*Scd1*, *Elovl6*, *Gpat*) as well as the lipogenic transcription factor Peroxisome proliferator-activated receptor gamma (*Ppar γ*). Data were normalized to TBP mRNA expression levels and to the vehicle-treated mice for each genotype. Statistical significance was evaluated using the unpaired Two-tailed Student's t test. Values shown are the mean \pm SEM.




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7

Table 1: Oligonucleotide sequences for real time PCR.

Gene	NCBI Refseq	Forward primer (5'-3')	Reverse primer (5'-3')
<i>Mus musculus</i>			
<i>Chrebpa</i>	NM_021455	CGACACTCACCCACCTCTTC	TTGTTTCAGCCGGATCTTGTC
<i>Chrebpb</i>	NM_021455	TCTGCAGATCGCGTGGAG	CTTGTCCTCCGGCATAGCAAC
<i>Cyp2b10</i>	NM_009999	TTTCTGCCCTTCTCAACAGGA	ATGGACGTGAAGAAAAGGAA
<i>Cyp2c29</i>	NM_007815	A	CAAC
<i>Cyp3a11</i>	NM_007818	GCTCAAAGCCTACTGTCA	CATGAGTGTAAATCGTCTCA
<i>Elovl6</i>	NM_130450	TCACACACACAGTTGTAGGCA	GTTTACGAGTCCCATATCGGT
<i>Fasn</i>	NM_007988	GAA	AGAG
<i>Gck</i>	NM_010191	TCTGATGAACAAGCGAGCCA	TGGTCATCAGAATGTACAGCA
<i>Gpat</i>	NM_0081449	AGTCAGCTATGAAGCAATTGT	TGT
<i>Lpk</i>	NM_013631	GGA	CACCCAGACGCCAGTGTTTC
<i>Pparγ</i>	NM_0011273	AGGAGTTCTATAACCTGCTGC	GGTCTTCAAGCTGCTGCTGA
<i>Pepck</i>	30	GAT	GT
<i>Pnpla2</i>	NM_025802	AGACGAAGCCTTCCGACGA	TGGACATGATAGCGCAGGAC
<i>Pnpla3</i>	NM_054088	TCGACTCAGAGCCTGTGGC	T
<i>Pnpla5</i>	NM_029427	GACCAACAGCCTGACGGG	AGTCGTGCAATGTTTCATCCCT
<i>Scd1</i>	NM_009127	GAACCCCAGCCTGCCC	TGAATATCAGTGGTTCACCGC
<i>Srebp1c</i>	NM_011480	GGATATCTTCAGGGACATCAG	TT
<i>Tbp</i>	NM_013684	GC	GAGCAACTCCAAAAAACCCG
<i>Thrsp-Spot14</i>	NM_009381	AGTGTCCCTTACCATCCGCTT	GGATATCTTCAGGGACATCAG
		ACGCGGTCACCTTCGTGT	GC
		GCTACTGCCCTGTACACTGCC	AGCCCGTCTCTGATGCACTT
		CAGTGCCGCGCATCTCTAT	GATGCTCCTCATCCAATCCAA
		GGAGCCATGGATTGCACATT	CAGCGGTACTCACTGGCAGA
		ATAGGATGAGGGTCTTAAGCC	GCTTCCAGAGAGGAGGCCAG
		TGTG	GGTTTGTATATGCTTGGGCCA
			G
<i>Homo Sapiens</i>			
<i>ACC</i>	NM_198834	AACGGAGGAGGCCGAAGAAG	GTTGATGCACCTCGGGGTCT
		CAGGCTGGCAGCTATGTTCA	GCCGGATCCCATGGTCA

<i>β</i> ACTIN	NM_001101	AGGCCCCCCTGAACCC	ATCACGATGCCAGTGGTACG
<i>ChREBP</i>	NM_032951	TTCCTCGGCCATGACCC	AGGAGGAAATCAGAACTCAG
<i>CYP2B6</i>	NM_000767	GGAGGAGCGGATTCAGGAG	GAAG
<i>LPK=PKLR</i>	NM_000298	TGCTGCTGCCATCATTGTG	TGGAATCGTTTTCCAAAGACG
<i>PNPLA3</i>	NM_025225	ACCCTCTCGCCCAGGCT	GGTACCGAGACAGAAGCTGG
<i>PSMB6</i>	NM_0012704	CAGAACAACCACTGGGTCTTA	G
	81	CA	CACCTTTGTCTTTCATTCTTC
<i>SCD1</i>	NM_005063	CCTGCAAGTTCTACACCTGGC	ACTC
		T	AGCAGAAAATGCGGTCGTG
<i>SREBP1C</i>	NM_004176.	GGCGAGCCGTGCGAT	CCCAGGGCACTGACAAAATA
	4		G
			TGCCCCACTCCCAGCAT

Table 2. Clinical characteristics of the liver donors.

Liver Identification	Sex	Age	Pathology
PHH367	M	59	Cholangiocarcinoma
PHH374	F	41	Adenoma
PHH366	M	62	Metastasis of colorectal cancer
PHH486	F	78	Hepatocellular carcinoma

F = female; M = male; PHH = primary human hepatocyte; Age in years.

Table 3. Body weight, relative liver weight and plasma parameters

	WT vehicle	WT TCPOBOP	CAR-/- vehicle	CAR-/- TCPOBOP
Mean body weight (g)	23.8 ± 0.60	23.7 ± 0.63	25.6 ± 0.77	25.5 ± 0.89
Liver : body weight ratio	0.04 ± 0.001 ^b	0.06 ± 0.001 ^b	0.04 ± 0.001	0.04 ± 0.001
Plasma glucose (mmol/L)	5.32 ± 0.30	4.19 ± 0.41 ^a	7.72 ± 0.32 ^b	7.65 ± 0.56
Plasma insulin (ng/mL)	0.39 ± 0.06	0.30 ± 0.04	0.56 ± 0.14	0.49 ± 0.10
Plasma triglycerides (mmol/L)	0.85 ± 0.07	0.61 ± 0.02 ^a	1.04 ± 0.11 ^b	1.02 ± 0.07

Body weight, relative liver weight and plasma parameters of WT and CAR-/- mice (n=6 males) treated with either vehicle (corn oil) or TCPOBOP (3 mg/kg/day) for 3 days. The statistical significance was evaluated using two-way ANOVA followed by *Tukey's post hoc test* (a: treatment effect, TCPOBOP vs vehicle; b, genotype effect, CAR-/- vs WT; p<0.05). Values are mean ± SEM.

Highlights

- Induction of hepatic glycolytic and lipogenic genes upon CAR activation by TCPOBOP
- These effects are not mediated by the nuclear receptor LXR
- CAR activation resulted in hepatic lipid accumulation
- Pnpla3 expression is regulated by CAR in mouse liver and human hepatocytes